Sucharita Mistry, PhD

Sparing the hippocampus did not increase the risk of brain metastasis.

The excess risk of cardiovascular disease from involved-field radiotherapy was 6.2%.

Certain treatments were associated with an increased risk of death unrelated to testicular cancer.

There was no significant difference in the risk of hypersensitivity reactions with low-dose or high-dose dexamethasone.

Responses improved over time, and the best overall response rate was 85%.

The objective response rate was 23.1%, and the disease control rate was 84.3%.

Next-generation sequencing provided actionable information for patients with uterine cancer.

Rucaparib was active in patients with germline BRCA2, germline PALB2, and somatic BRCA2 variants.

Patients who received daratumumab were more likely to be MRD negative at 12 months and beyond.

The median duration of response was 10.8 months.